January 7, 2014
Efficacy of a Systemic Enzyme Formulation in the Treatment of Shoulder Tendonitis
Szczurko O, Cooley K, Mills EJ, Zhou Q, Perri D, Seely D. Naturopathic treatment of rotator cuff tendinitis among Canadian postal workers: a randomized controlled trial. Arthritis Rheum. 2009;61(8):1037-1045.
A prospective randomized clinical trial.
Canadian postal workers with rotator cuff tendonitis/tendinitis for a duration of greater than 6 weeks. The “Naturopathic Care” group had 43 members, of whom 25 were women and 18 were men. The “Physical Exercise” group had 42 members, of whom 25 were women and 17 were men.
Patients were randomized to “Naturopathic Care” (NC) which included acupuncture, recommendation of an anti-inflammatory diet, and Phlogenzym® (which is called Wobenzym® PS in the United States), and enteric-coated polyenzyme formulation containing trypsin, bromelain and rutin; or to the “Physical Exercise” (PE) group, which included physical exercise, hands-on shoulder muscle and joint therapy, and matched placebo tablets. Both groups consisted of well-developed therapeutic doctor-patient relationships, patient motivation, and consumption of a pill.
The primary outcome measure was the Shoulder Pain and Disability Index (SPADI), and secondary outcomes were the pain Visual Analog Scale (VAS), Short Form 36 (SF-36), Measure Yourself Medical Outcomes Profile (MYMOP), and shoulder maximal range of motion.
Final total SPADI scores decreased by 54.5% in the NC group and by 18% in the PE group. Between-group differences in changes to SPADI scores showed statistically significant decreases in shoulder pain and disability in the NC group compared with the PE group. Significant differences between groups were also observed in the VAS, MYMOP, SF-36, and shoulder extension, flexion, and abduction, with the NC group showing superiority in each outcome.
Naturopathic care that included acupuncture and Phlogenzym®/Wobenzym® PS dramatically improved patient outcomes compared to standard physical therapy. Significant results were achieved within 8 weeks of treatment and no serious adverse events were reported. A recent study by Lathia, et al, reported that acupuncture may be an effective treatment for chronic shoulder pain.1 Although it is not possible to isolate the role of Phlogenzym®/Wobenzym® PS in this small study design, improvement in periarthritis humeroscapularis tendopathy was previously reported by Kullich and Klein, in a study in which Phlogenzym®/Wobenzym® PS was at least as successful as the non-steroidal anti-inflammatory drug diclofenac, with a moderate superiority of the enzyme formulation when calculated by the Mann-Whitney statistics.2 Further, Szczurko and colleagues rightly point out that the Phlogenzym®/Wobenzym® PS formulation has demonstrated anti-inflammatory effects in a number of previous studies related to diseases or trauma of the joints, including osteoarthritis, rheumatic disease, and traumatic injury.3,4,5,6 In addition to shoulders, treatment with Phlogenzym®/Wobenzym® PS has also demonstrated improvement of function in knee and hip joints, including decreased pain and has been used as an adjuvant in the treatment of rheumatoid arthritis.7,8,9 Inflammatory tendinitis is mediated at least in part by cytokines, including elevated levels of TGF-beta.10 It has previously been reported that intestinal absorption of the Phlogenzym®/Wobenzym® PS formulation triggers the formation of TGF-beta binding species of alpha-2-macroglobulin (a naturally occurring serum protein), such that high concentrations of TGF-beta are reduced via enhanced clearance of alpha-2-macroglobulin-TGF-beta complexes.11 Noting that the Phlogenzym®/Wobenzym® PS formulation was used successfully in conjunction with diet and acupuncture and observing that multimodal therapies are common in both naturopathic and allopathic medicine, Phlogenzym®/Wobenzym® PS might be a reasonable adjuvant, or component of comprehensive treatment, for the management of inflammatory joint pain.
- Lathia AT, Jung SM, Chen LX. Efficacy of acupuncture as a treatment for chronic shoulder pain. J Altern Complement Med. 2009;15(6):613-618.
- Kullich W, Klein G. Treatment with oral enzymes in painful osteoarthritis of the knee and periarthritis of the shoulder. Reumatologia. 1998;213(Suppl 36):111-114.
- Tilwe GH, Beria S, Turakhia NH, Daftary GV, Schiess W. Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthrosis of knee joint: an open randomized controlled clinical trial. J Assoc Physicians India. 2001;49:617-621.
- Wittenborg A, Bock PR, Hanisch J, Saller R, Schneider B. Comparative epidemiological study in patients with rheumatic diseases illustrated in an example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination preparation. Arzneimittelforschung 2000;50:728-738.
- Klein G, Kullich W. Reducing pain by oral enzyme therapy in rheumatic diseases. Wien Med Wochenschr. 1999;149:577-580.
- Kamenicek V, Holan P, Franek P. Systemic enzyme therapy in the treatment and prevention of post-traumatic and postoperative swelling. Acta Chir Orthop Traumatol Cech. 2001;68:45-49.
- Wittenborg A, Bock PR, Hanisch J, Saller R, Schneider B. Comparative epidemiological study in patients with rheumatic diseases illustrated in an example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination preparation. Arzneimittelforschung. 2000;50:728-738.
- Klein G, Kullich W, Schnitker J, Schwann H. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2006;24(1):25-30.
- Mazourov VI, Lila AM, Klimko NN, Raimue KV, Makulova TG. The role of systemic enzymotherapy in the treatment of rheumatoid arthritis. Reumatologia. 1998;211(Suppl 36), 108-110.
- Fu SC, Wang W, Pau HM, Wong YP, Chan KM, Rolf CG. Increased expression of transforming growth factor-beta1 in patellar tendinosis. Clin Orthop Relat Res. 2002;(400):174-183.
- Lauer D, Müller R, Cott C, Otto A, Naumann M, Birkenmeier G. Modulation of growth factor binding properties of alpha2-macroglobulin by enzyme therapy. Cancer Chemother Pharmacol. 2001;47:S4-9.